Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1994 Aug;62(8):3447–3453. doi: 10.1128/iai.62.8.3447-3453.1994

Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H- in mitomycin-treated mice.

J Fujii 1, T Kita 1, S Yoshida 1, T Takeda 1, H Kobayashi 1, N Tanaka 1, K Ohsato 1, Y Mizuguchi 1
PMCID: PMC302977  PMID: 8039916

Abstract

We developed a mouse model of acute encephalopathy induced by verotoxin 2 variant (VT2v)-producing Escherichia coli. Three-week-old mice were inoculated intragastrically with approximately 10(10) CFU of E. coli O157:H- strain E32511/HSC and simultaneously given an intraperitoneal injection of mitomycin (MMC; 2.5 mg/kg). Drinking water containing 5 g of streptomycin sulfate per liter was given ad libitum from 3 days before the infection. From 1 to 2 days after bacterial inoculation, clinical features including weight loss, weakness, and flaccid paralysis of the extremities developed, usually culminating in death within 4 days. Diarrhea was not observed during the course of disease. No mice died in the absence of streptomycin or MMC treatment for 2 weeks after the oral bacterial infection. Judging from the clinical course and the biochemical and histological examination, the cause of death was not likely to be attributable to renal failure or to a side effect of MMC. To better understand the cause of death, we examined the brain cortex and spinal cord of the moribund mice by electron microscopy. Mice showing mortal symptoms were given horseradish peroxidase intravenously. The tracer was present in the endothelial basal lamina, in the surrounding extracellular spaces, and even in the neuron fibers of the brain cortex. Furthermore, immunoreactivity of VT2v, proved by the use of rabbit anti-VT2 serum, was localized selectively in the damaged myelin sheaths of neuron fibers which were accompanied by edematous axons in the brain cortex and spinal cord. These findings strongly suggest that VT2v is toxic to both endothelial cells and neurons in the central nervous system and subsequently causes fatal acute encephalopathy.

Full text

PDF
3447

Images in this article

3450Image
on p.3450
3450Image
on p.3450
3450Image
on p.3450
3450Image
on p.3450
3451Image
on p.3451

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antman K. H., Skarin A. T., Mayer R. J., Hargreaves H. K., Canellos G. P. Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore) 1979 Sep;58(5):377–384. doi: 10.1097/00005792-197909000-00004. [DOI] [PubMed] [Google Scholar]
  2. BRIDGWATER F. A., MORGAN R. S., ROWSON K. E., WRIGHT G. P. The neurotoxin of Shigella shigae: morphological and functional lesions produced in the central nervous system of rabbits. Br J Exp Pathol. 1955 Oct;36(5):447–453. [PMC free article] [PubMed] [Google Scholar]
  3. Barrett T. J., Potter M. E., Wachsmuth I. K. Bacterial endotoxin both enhances and inhibits the toxicity of Shiga-like toxin II in rabbits and mice. Infect Immun. 1989 Nov;57(11):3434–3437. doi: 10.1128/iai.57.11.3434-3437.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. HOWARD J. G. Observations on the intoxication produced in mice and rabbits by the neurotoxin of Shigella shigae. Br J Exp Pathol. 1955 Oct;36(5):439–446. [PMC free article] [PubMed] [Google Scholar]
  5. Hamano S., Nakanishi Y., Nara T., Seki T., Ohtani T., Oishi T., Joh K., Oikawa T., Muramatsu Y., Ogawa Y. Neurological manifestations of hemorrhagic colitis in the outbreak of Escherichia coli O157:H7 infection in Japan. Acta Paediatr. 1993 May;82(5):454–458. doi: 10.1111/j.1651-2227.1993.tb12721.x. [DOI] [PubMed] [Google Scholar]
  6. Hii J. H., Gyles C., Morooka T., Karmali M. A., Clarke R., De Grandis S., Brunton J. L. Development of verotoxin 2- and verotoxin 2 variant (VT2v)-specific oligonucleotide probes on the basis of the nucleotide sequence of the B cistron of VT2v from Escherichia coli E32511 and B2F1. J Clin Microbiol. 1991 Dec;29(12):2704–2709. doi: 10.1128/jcm.29.12.2704-2709.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Karmali M. A. Infection by verocytotoxin-producing Escherichia coli. Clin Microbiol Rev. 1989 Jan;2(1):15–38. doi: 10.1128/cmr.2.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Karmali M. A., Petric M., Lim C., Fleming P. C., Arbus G. S., Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis. 1985 May;151(5):775–782. doi: 10.1093/infdis/151.5.775. [DOI] [PubMed] [Google Scholar]
  9. Karmali M. A., Steele B. T., Petric M., Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1983 Mar 19;1(8325):619–620. doi: 10.1016/s0140-6736(83)91795-6. [DOI] [PubMed] [Google Scholar]
  10. Karnovsky M. J. The ultrastructural basis of capillary permeability studied with peroxidase as a tracer. J Cell Biol. 1967 Oct;35(1):213–236. doi: 10.1083/jcb.35.1.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kaye S. A., Louise C. B., Boyd B., Lingwood C. A., Obrig T. G. Shiga toxin-associated hemolytic uremic syndrome: interleukin-1 beta enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro. Infect Immun. 1993 Sep;61(9):3886–3891. doi: 10.1128/iai.61.9.3886-3891.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kleanthous H., Smith H. R., Scotland S. M., Gross R. J., Rowe B., Taylor C. M., Milford D. V. Haemolytic uraemic syndromes in the British Isles, 1985-8: association with verocytotoxin producing Escherichia coli. Part 2: Microbiological aspects. Arch Dis Child. 1990 Jul;65(7):722–727. doi: 10.1136/adc.65.7.722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lindgren S. W., Melton A. R., O'Brien A. D. Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model. Infect Immun. 1993 Sep;61(9):3832–3842. doi: 10.1128/iai.61.9.3832-3842.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lingwood C. A., Law H., Richardson S., Petric M., Brunton J. L., De Grandis S., Karmali M. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem. 1987 Jun 25;262(18):8834–8839. [PubMed] [Google Scholar]
  15. Louise C. B., Obrig T. G. Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. Infect Immun. 1992 Apr;60(4):1536–1543. doi: 10.1128/iai.60.4.1536-1543.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Louise C. B., Obrig T. G. Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect Immun. 1991 Nov;59(11):4173–4179. doi: 10.1128/iai.59.11.4173-4179.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. MacLeod D. L., Gyles C. L. Effects of culture conditions on yield of Shiga-like toxin-IIv from Escherichia coli. Can J Microbiol. 1989 Jun;35(6):623–629. doi: 10.1139/m89-100. [DOI] [PubMed] [Google Scholar]
  18. Milford D. V., Taylor C. M., Guttridge B., Hall S. M., Rowe B., Kleanthous H. Haemolytic uraemic syndromes in the British Isles 1985-8: association with verocytotoxin producing Escherichia coli. Part 1: Clinical and epidemiological aspects. Arch Dis Child. 1990 Jul;65(7):716–721. doi: 10.1136/adc.65.7.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Morrison D. M., Tyrrell D. L., Jewell L. D. Colonic biopsy in verotoxin-induced hemorrhagic colitis and thrombotic thrombocytopenic purpura (TTP). Am J Clin Pathol. 1986 Jul;86(1):108–112. doi: 10.1093/ajcp/86.1.108. [DOI] [PubMed] [Google Scholar]
  20. Myhal M. L., Laux D. C., Cohen P. S. Relative colonizing abilities of human fecal and K 12 strains of Escherichia coli in the large intestines of streptomycin-treated mice. Eur J Clin Microbiol. 1982 Jun;1(3):186–192. doi: 10.1007/BF02019621. [DOI] [PubMed] [Google Scholar]
  21. Noda M., Yutsudo T., Nakabayashi N., Hirayama T., Takeda Y. Purification and some properties of Shiga-like toxin from Escherichia coli O157:H7 that is immunologically identical to Shiga toxin. Microb Pathog. 1987 May;2(5):339–349. doi: 10.1016/0882-4010(87)90076-3. [DOI] [PubMed] [Google Scholar]
  22. O'Brien A. D., Holmes R. K. Shiga and Shiga-like toxins. Microbiol Rev. 1987 Jun;51(2):206–220. doi: 10.1128/mr.51.2.206-220.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. O'Brien A. D., Newland J. W., Miller S. F., Holmes R. K., Smith H. W., Formal S. B. Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea. Science. 1984 Nov 9;226(4675):694–696. doi: 10.1126/science.6387911. [DOI] [PubMed] [Google Scholar]
  24. Oku Y., Yutsudo T., Hirayama T., O'Brien A. D., Takeda Y. Purification and some properties of a Vero toxin from a human strain of Escherichia coli that is immunologically related to Shiga-like toxin II (VT2). Microb Pathog. 1989 Feb;6(2):113–122. doi: 10.1016/0882-4010(89)90014-4. [DOI] [PubMed] [Google Scholar]
  25. Ostroff S. M., Tarr P. I., Neill M. A., Lewis J. H., Hargrett-Bean N., Kobayashi J. M. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis. 1989 Dec;160(6):994–998. doi: 10.1093/infdis/160.6.994. [DOI] [PubMed] [Google Scholar]
  26. Richardson S. E., Rotman T. A., Jay V., Smith C. R., Becker L. E., Petric M., Olivieri N. F., Karmali M. A. Experimental verocytotoxemia in rabbits. Infect Immun. 1992 Oct;60(10):4154–4167. doi: 10.1128/iai.60.10.4154-4167.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Riley L. W., Remis R. S., Helgerson S. D., McGee H. B., Wells J. G., Davis B. R., Hebert R. J., Olcott E. S., Johnson L. M., Hargrett N. T. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med. 1983 Mar 24;308(12):681–685. doi: 10.1056/NEJM198303243081203. [DOI] [PubMed] [Google Scholar]
  28. Rooney J. C., Anderson R. M., Hopkins I. J. Clinical and pathological aspects of central nervous system involvement in the haemolytic uraemic syndrome. Aust Paediatr J. 1971 Mar;7(1):28–33. doi: 10.1111/j.1440-1754.1971.tb02465.x. [DOI] [PubMed] [Google Scholar]
  29. Schmitt C. K., McKee M. L., O'Brien A. D. Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511. Infect Immun. 1991 Mar;59(3):1065–1073. doi: 10.1128/iai.59.3.1065-1073.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Scotland S. M., Willshaw G. A., Smith H. R., Rowe B. Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2. Epidemiol Infect. 1987 Dec;99(3):613–624. doi: 10.1017/s0950268800066462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Shi Z. R., Itzkowitz S. H., Kim Y. S. A comparison of three immunoperoxidase techniques for antigen detection in colorectal carcinoma tissues. J Histochem Cytochem. 1988 Mar;36(3):317–322. doi: 10.1177/36.3.3278057. [DOI] [PubMed] [Google Scholar]
  32. Strockbine N. A., Marques L. R., Newland J. W., Smith H. W., Holmes R. K., O'Brien A. D. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect Immun. 1986 Jul;53(1):135–140. doi: 10.1128/iai.53.1.135-140.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Tesh V. L., Burris J. A., Owens J. W., Gordon V. M., Wadolkowski E. A., O'Brien A. D., Samuel J. E. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect Immun. 1993 Aug;61(8):3392–3402. doi: 10.1128/iai.61.8.3392-3402.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Thomas A., Smith H. R., Rowe B. Use of digoxigenin-labelled oligonucleotide DNA probes for VT2 and VT2 human variant genes to differentiate Vero cytotoxin-producing Escherichia coli strains of serogroup O157. J Clin Microbiol. 1993 Jul;31(7):1700–1703. doi: 10.1128/jcm.31.7.1700-1703.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Tyler S. D., Johnson W. M., Lior H., Wang G., Rozee K. R. Identification of verotoxin type 2 variant B subunit genes in Escherichia coli by the polymerase chain reaction and restriction fragment length polymorphism analysis. J Clin Microbiol. 1991 Jul;29(7):1339–1343. doi: 10.1128/jcm.29.7.1339-1343.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Tzipori S., Chow C. W., Powell H. R. Cerebral infection with Escherichia coli O157:H7 in humans and gnotobiotic piglets. J Clin Pathol. 1988 Oct;41(10):1099–1103. doi: 10.1136/jcp.41.10.1099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Upadhyaya K., Barwick K., Fishaut M., Kashgarian M., Siegel N. J. The importance of nonrenal involvement in hemolytic-uremic syndrome. Pediatrics. 1980 Jan;65(1):115–120. [PubMed] [Google Scholar]
  38. Valavaara R., Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose. Cancer. 1985 Jan 1;55(1):47–50. doi: 10.1002/1097-0142(19850101)55:1<47::aid-cncr2820550108>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  39. Waddell T., Head S., Petric M., Cohen A., Lingwood C. Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2. Biochem Biophys Res Commun. 1988 Apr 29;152(2):674–679. doi: 10.1016/s0006-291x(88)80091-3. [DOI] [PubMed] [Google Scholar]
  40. Wadolkowski E. A., Burris J. A., O'Brien A. D. Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli O157:H7. Infect Immun. 1990 Aug;58(8):2438–2445. doi: 10.1128/iai.58.8.2438-2445.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Wadolkowski E. A., Sung L. M., Burris J. A., Samuel J. E., O'Brien A. D. Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II. Infect Immun. 1990 Dec;58(12):3959–3965. doi: 10.1128/iai.58.12.3959-3965.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Westergaard E. The blood-brain barrier to horseradish peroxidase under normal and experimental conditions. Acta Neuropathol. 1977 Aug 31;39(3):181–187. doi: 10.1007/BF00691695. [DOI] [PubMed] [Google Scholar]
  43. Wiley R. G., Donohue-Rolfe A., Keusch G. T. Axonally transported Shigella cytotoxin is neuronotoxic. J Neuropathol Exp Neurol. 1985 Sep;44(5):496–506. doi: 10.1097/00005072-198509000-00005. [DOI] [PubMed] [Google Scholar]
  44. Yee A. J., De Grandis S., Gyles C. L. Mitomycin-induced synthesis of a Shiga-like toxin from enteropathogenic Escherichia coli H.I.8. Infect Immun. 1993 Oct;61(10):4510–4513. doi: 10.1128/iai.61.10.4510-4513.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Yutsudo T., Nakabayashi N., Hirayama T., Takeda Y. Purification and some properties of a Vero toxin from Escherichia coli O157:H7 that is immunologically unrelated to Shiga toxin. Microb Pathog. 1987 Jul;3(1):21–30. doi: 10.1016/0882-4010(87)90034-9. [DOI] [PubMed] [Google Scholar]
  46. Zoja C., Corna D., Farina C., Sacchi G., Lingwood C., Doyle M. P., Padhye V. V., Abbate M., Remuzzi G. Verotoxin glycolipid receptors determine the localization of microangiopathic process in rabbits given verotoxin-1. J Lab Clin Med. 1992 Aug;120(2):229–238. [PubMed] [Google Scholar]
  47. al-Jumaili I., Burke D. A., Scotland S. M., al-Mardini H., Record C. O. A method of enhancing verocytotoxin production by Escherichia coli. FEMS Microbiol Lett. 1992 Jun 1;72(2):121–125. doi: 10.1016/0378-1097(92)90516-q. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES